MIRM News and Press, Mirum Pharmaceuticals Inc. From 04/23/24

2024-04-23 13:12:48 ET Summary The recent lack of M&A activity and rising interest rates have helped trigger an approximate 20% decline in small-cap biotech equities. Drug blockbusters facing key patent expirations and Big Pharma's surplus of cash suggest increased M&A vol...

2024-04-22 15:04:08 ET Summary The FDA approved Mirum Pharmaceuticals, Inc.'s Limvarli for treatment of cholestatic pruritus in patients with Progressive Familial Intrahepatic Cholestasis; Potential for further label expansion in younger patients possible due to positive MARCH study. ...

2024-04-21 10:49:18 ET Summary The yield on the 10-Year Treasury has risen to 4.62% from under 3.9% in late February. Rising rates are taking an increasing toll on the market, as the S&P 500 posted its worst weekly performance since March of 2023 this week. Bubbles in the ...

2024-04-18 10:39:58 ET More on Mirum Pharmaceuticals Mirum Pharmaceuticals: Advancing On Several Key Fronts Mirum Pharmaceuticals, Inc. (MIRM) Q4 2023 Earnings Call Transcript Mirum Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation Mirum&#x...

2024-04-16 18:00:02 ET Dae Gon Ha from Stifel Nicolaus issued a price target of $48.00 for MIRM on 2024-04-16 16:20:00. The adjusted price target was set to $48.00. At the time of the announcement, MIRM was trading at $24.01. The overall price target consensus is at $57....

2024-04-16 06:15:04 ET Citigroup analyst issues BUY recommendation for MIRM on April 16, 2024 04:53AM ET. The previous analyst recommendation was Buy. MIRM was trading at $23.91 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current anal...

2024-04-13 05:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-04-02 08:59:39 ET More on Mirum Pharmaceuticals Mirum Pharmaceuticals: Advancing On Several Key Fronts Mirum Pharmaceuticals, Inc. (MIRM) Q4 2023 Earnings Call Transcript Mirum Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation Mirum ga...

- Positive HTA recommendation for reimbursement signifies an important milestone towards public funding to treat eligible patients with this rare liver disorder - LIVMARLI is the first and only approved medication to treat cholestatic pruritus in patients with Alagille syndrome in Canad...

SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointme...